Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Great Portland Estates shares 'good value' after recent falls, says Shore Capital

(Sharecast News) - Great Portland Estates is "worth a revisit" for investors following its recent share price weakness, according to Shore Capital, which reiterated a 'buy' rating on the stock on Friday. Shares in the London-focused real estate group have dropped by around 11% over the past month - something which Shore Capital said was "largely associated with the softening of bond yields".

The broker highlighted several reasons for investors to be optimistic, including: a stabilising office market in Central London, increased rental prices and stable yields, a recovery in transaction activity and strong occupier demand.

"This is fuelling further ERV growth - with company guidance of 4-7% for the financial year and prime spaces higher still (6-10%) where vacancy is close to zero and demand well outstripping the supply of both new and refurbished space," said analyst Andrew Saunders.

Despite a strong operational performance from GPE - as confirmed in July's first-quarter update - Shore Capital remains bullish, particularly since the share price is trading at a 42% discount to estimate net tangible asset estimates for 2026.

"With the company noting transaction activity picking up and a significant pipeline of new acquisition opportunities beginning to emerge, the shares continue to offer good value and we reiterate our BUY recommendation," Saunders said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.